The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020. Vertex Pharmaceuticals is betting nearly $1 billion on a company developing a stem cell-based therapy and device with the stated goal of creating a potentially curative treatment for Type 1 diabetes, though it is still preclinical. Boston-based Vertex said Tuesday that it would pay $950 million to buy Semma Therapeuticis, a privately held company based on nearby Cambridge. The company is developing a therapy using stem cell-derived human islets.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
bacteria
binx health
Biosimilar
Blood Filter
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
colorectal cancer
Diagnostics
Digital Health
Drug Discovery
ExThera Medical
FDA
FDA approval
funding
fundraising
glycosylation
Halodoc
HIV
Innovation
Licensing
M&A
medical device
medtech
microbial
microbial DNA
microbial RNA
microbiome
Neuro
Novartis
pharma
Pharming
Prescient Metabiomics
robots
software
Therapeutics
Therapy
USA
VIrology
women health